Skip to main content
OpenTrials
Completed

NCT Number: NCT05525806

Clinical Utility Study for MyProstateScore+

This is a national-level research study of urologists. The purpose of this study is to assess the clinical evaluation and management (drug, procedures, counseling and other) of a subset of common patient care indications.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Prostate Cancer Genital Diseases Genital Diseases, Male Genital Neoplasms, Male Male Urogenital Diseases Neoplasms Neoplasms by Site Prostatic Diseases Prostatic Neoplasms Urogenital Diseases Urogenital Neoplasms

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

QURE Healthcare

San Francisco, California, 94109, United States

About this study

The results of this study could contribute to improved quality of care for patients by encouraging better care practices and adherence to evidence-based guidance. The data from this study will be submitted to a national journal for publication. The study plans to enroll up to 250 physicians.

Upon consenting and agreeing to participate in this study, participants will be asked to care for 3 simulated patient cases, known as Clinical Performance and Value Vignettes (CPV®). CPVs describe patients physicians typically encounter in their daily practice and are not meant to be difficult. In each vignette, physicians are asked to share their expected care through 5 domains: 1) history, 2) physical exam, 3) diagnostic workup, 4) diagnosis and 5) treatment and follow-up. Each case takes approximately 15-20 minutes to complete and we estimate the time commitment for each round of CPV administration to be approximately 45 - 60 minutes. All responses to the cases will be completed online and will be kept confidential. Over 2 CPV administration rounds, the total time to care for the simulated patients is estimated at 1.5-2 hours.

If physicians are randomized to an intervention group in this study, they will receive education materials on a novel diagnostic test after the first round of CPV administration. They are asked to review these materials before moving to the next CPV administration round. Time to review education materials is estimated to be approximately 15 minutes.

Depending on the results of this randomized controlled trial, there may be an opportunity for physicians to re-enroll into a follow-on study. If they choose to participate in this second study, they will be asked to identify and send de-identified records of patients in their practice that are similar to the simulated patients they previously cared for in this study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Board-certified urologists for at least two years
  • Averaging at least 20 hours per week of clinical and patient care duties over the last six months
  • Routinely evaluate patients at risk for prostate cancer in their practice
  • Practicing in the U.S.
  • English speaking
  • Access to the internet
  • Informed, signed and voluntarily consented to be in the study

Exclusion criteria

  • Non-English speaking
  • Unable to access the internet
  • Not practicing in the U.S.
  • Not averaging at least 20 hours per week of clinical or patient care duties over the last six months
  • Previous exposure to the MyProstateScore test
  • Do not voluntarily consent to be in the study

Treatment and study plan

Education Materials for MyProstateScore

Other

These materials detail what the test does, how it is used, the validity and specifications of the test, and how to read its test report.

Other names: MyProstateScore results

Primary outcomes

  1. Clinical Performance and Value (CPV)-measured variation in Assessment

    Time frame: [4 months]

    Measuring the rates of ordering prostate biopsy with proper assessment, recognition, and management of prostate cancer risks in patients with different PSA levels, a negative previous prostate biopsy, and an elevated PI-RADS score.

  2. CPV-measured change in treatment Quality

    Time frame: [4 months]

    Measure of the difference in quality of overall diagnostic scores between control physicians using standard of care diagnostic tools and intervention physicians using the MyProstateScore test.

  3. CPV-measured variation in evidence based decisions between control and intervention arms

    Time frame: [4 months]

    Measure of the difference in number of evidence-based decisions made by intervention physicians versus control physicians, while controlling for physician and practice characteristics, between rounds 1 and 2.

  4. CPV-measured variation in evidence based decisions between intervention arms

    Time frame: [4 months]

    Measure the differences in amount of evidence-based decisions made by intervention group one physicians versus intervention group two physicians to assess whether the choice to order the MyProstateScore test impacts the frequency of prostate biopsies and overall patient care and outcomes.

  5. CPV-measured rate of adoption for MyProstateScore

    Time frame: [4 months]

    Rate of adoption of the MyProstateScore test after receiving educational materials on the benefits of testing in patients who are at risk.

  6. CPV-measured differences in cost of care between control and intervention arms

    Time frame: [4 months]

    Difference in the cost of care between control and intervention physicians (Cost will be calculated by measuring differential rates of medical interventions/levels of care selected by each arm, and multiplying by Medicare reimbursement rates for these interventions, and/or by modeling the incidence of expected complications and calculating associated costs per above).

Sponsors and collaborators

Lead sponsor

Qure Healthcare, LLC

Industry

Registry information

Official study title

Establishing Clinical Utility Evidence to Support Coverage and Reimbursement for LynxDx's MyProstateScore Test: A CPV® Randomized Controlled Trial

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Sep 2, 2022
Registry last updated
Jun 13, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.